144 related articles for article (PubMed ID: 20003422)
1. Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan.
Waning B; Maddix J; Tripodis Y; Laing R; Leufkens HG; Gokhale M
Int J Equity Health; 2009 Dec; 8():43. PubMed ID: 20003422
[TBL] [Abstract][Full Text] [Related]
2. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
Waning B; Maddix J; Soucy L
BMC Health Serv Res; 2010 Jul; 10():205. PubMed ID: 20626904
[TBL] [Abstract][Full Text] [Related]
3. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan.
Vogler S; Schneider P; Dedet G; Bak Pedersen H
Int J Equity Health; 2019 Jun; 18(1):89. PubMed ID: 31196109
[TBL] [Abstract][Full Text] [Related]
4. Prices of medicines for the management of pain, diabetes and cardiovascular diseases in private pharmacies and the national health insurance in Tanzania.
Kirua RB; Temu MJ; Mori AT
Int J Equity Health; 2020 Nov; 19(1):203. PubMed ID: 33172498
[TBL] [Abstract][Full Text] [Related]
5. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia.
Babar ZU; Ibrahim MI; Singh H; Bukahri NI; Creese A
PLoS Med; 2007 Mar; 4(3):e82. PubMed ID: 17388660
[TBL] [Abstract][Full Text] [Related]
6. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
7. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia.
Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J
PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889
[TBL] [Abstract][Full Text] [Related]
8. Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria.
Orubu ESF; Robert FO; Samuel M; Megbule D
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii20-iii26. PubMed ID: 31816074
[TBL] [Abstract][Full Text] [Related]
9. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.
Yang H; Dib HH; Zhu M; Qi G; Zhang X
Health Policy Plan; 2010 May; 25(3):219-29. PubMed ID: 19955093
[TBL] [Abstract][Full Text] [Related]
10. Discounting of medicines in Australian community pharmacies.
Thai LP; Vitry AI; Moss JR
Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
[TBL] [Abstract][Full Text] [Related]
11. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
Puig-Junoy J
Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
[TBL] [Abstract][Full Text] [Related]
12. Prices & availability of common medicines at six sites in India using a standard methodology.
Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
[TBL] [Abstract][Full Text] [Related]
13. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
[TBL] [Abstract][Full Text] [Related]
14. Short-term differences in drug prices after implementation of the national essential medicines system: A case study in rural Jiangxi Province, China.
Wang J; Liu X; Wang S; Chen H; Wang X; Zhou W; Wang L; Zhu Y; Zheng X; Hao M
Indian J Pharmacol; 2015; 47(5):535-9. PubMed ID: 26600644
[TBL] [Abstract][Full Text] [Related]
15. Medicines prices in International (Geary-Khamis) Dollar. The comparison between regulated and deregulated markets.
Zaprutko T; Cynar J; Sygit M; Stolecka A; Skorupska P; Jaszcz P; Kopciuch D; Paczkowska A; Ratajczak P; Kus K
PLoS One; 2024; 19(6):e0304400. PubMed ID: 38848422
[TBL] [Abstract][Full Text] [Related]
16. Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology.
Sharma A; Rorden L; Ewen M; Laing R
J Pharm Policy Pract; 2016; 9():12. PubMed ID: 27054040
[TBL] [Abstract][Full Text] [Related]
17. Multi stakeholders of health and industries perspectives on medicine price transparency initiative in private health care settings in Malaysia.
Sufiza Ahmad N; Makmor-Bakry M; Hatah E
Saudi Pharm J; 2020 Jul; 28(7):850-858. PubMed ID: 32647487
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study.
Yang C; Hu S; Ye D; Jiang M; Babar ZU; Fang Y
Front Pharmacol; 2020; 11():602421. PubMed ID: 33381042
[No Abstract] [Full Text] [Related]
19. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
Kakani P; Chernew M; Chandra A
J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
[TBL] [Abstract][Full Text] [Related]
20. Inflated medicine prices in Vietnam: a qualitative study.
Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
Health Policy Plan; 2017 Jun; 32(5):647-656. PubMed ID: 28453716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
